MyRisk results help inform decisions primarily about what?

MyRisk results help inform decisions primarily about what?

• A. Immediate treatment of existing cancer
• B. Management decisions based on inherited cancer risk
• C. Donor eligibility for transplantation
• D. Vaccination strategies

Answer: (B)

Inherited cancer risk is all about how genetic variants carried in a person’s DNA affect their future cancer risk and how that information guides long‑term management. MyRisk results summarize which inherited variants a person may carry and translate that into personalized plans for surveillance and prevention. This means decisions about how often to screen, what types of screening to use, and whether to pursue risk‑reducing options (such as certain surgeries or preventive medications) are tailored to the specific inherited risk profile and family history. It also enables family members to be tested so each relative can adjust their own monitoring accordingly. This preventive, risk‑based approach is why the primary use is management decisions based on inherited cancer risk. It does not dictate immediate treatment of an existing cancer, does not determine donor eligibility for transplantation, and does not directly drive vaccination strategies.

Inherited cancer risk is all about how genetic variants carried in a person’s DNA affect their future cancer risk and how that information guides long‑term management. MyRisk results summarize which inherited variants a person may carry and translate that into personalized plans for surveillance and prevention. This means decisions about how often to screen, what types of screening to use, and whether to pursue risk‑reducing options (such as certain surgeries or preventive medications) are tailored to the specific inherited risk profile and family history. It also enables family members to be tested so each relative can adjust their own monitoring accordingly. This preventive, risk‑based approach is why the primary use is management decisions based on inherited cancer risk. It does not dictate immediate treatment of an existing cancer, does not determine donor eligibility for transplantation, and does not directly drive vaccination strategies.